Molecular Pathways Driving Omeprazole Nephrotoxicity [PDF]
Redox Biology, 2020 Omeprazole, a proton pump inhibitor used to treat peptic ulcer and gastroesophageal reflux disease, has been associated to chronic kidney disease and acute interstitial nephritis. However, whether omeprazole is toxic to renal cells is unknown. Omeprazole
Maria Dolores Sanchez-niño +2 more
exaly +4 more sources
Clinical Medicine Insights: Gastroenterology, 2017 Aim: To compare the efficacy and safety of omeprazole-domperidone combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD). Methods: In a comparative, randomized controlled, phase 4 study, outpatients with GERD were randomly ...
KY Marakhouski +3 more
doaj +3 more sources
Acid-Neutralizing Omeprazole Formulation for Rapid Release and Absorption
PharmaceuticsBackground/Objectives: Omeprazole undergoes degradation in acidic conditions, which makes it unstable in low pHs found in the gastric environment. The vast majority of already marketed omeprazole formulations use enteric polymer coatings to protect the ...
Sreela Ramesh +6 more
doaj +2 more sources
Impact of obesity and roux‐en‐Y gastric bypass on the pharmacokinetics of (R)‐ and (S)‐omeprazole and intragastric pH [PDF]
CPT: Pharmacometrics & Systems PharmacologyThis study employed physiologically‐based pharmacokinetic–pharmacodynamics (PBPK/PD) modeling to predict the effect of obesity and gastric bypass surgery on the pharmacokinetics and intragastric pH following omeprazole treatment.
Leandro F. Pippa +7 more
doaj +2 more sources
Binding of omeprazole to protein targets identified by monoclonal antibodies.
PLoS ONE, 2020 Omeprazole is the most commonly used proton pump inhibitor (PPI), a class of medications whose therapeutic mechanism of action involves formation of a disulfide linkage to cysteine residues in the H+/K+ ATPase pump on gastric secretory cells.
Naw May Pearl Cartee, Michael M Wang
doaj +3 more sources
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells.
PLoS ONE, 2011 BackgroundOmeprazole has recently been described as a modulator of tumour chemoresistance, although its underlying molecular mechanisms remain controversial.
Andrej Udelnow +9 more
doaj +2 more sources
Omeprazole as a Novel Treatment Option for Giardiasis in Cats [PDF]
Veterinary Medicine and ScienceBackground Giardiasis is a common protozoal infection in cats, often treated with nitroimidazole derivatives such as metronidazole and secnidazole. However, there are concerns about resistance to nitroimidazoles and their adverse effects. Recent in vitro
Murat Kaan Durgut +6 more
doaj +2 more sources
Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients. [PDF]
Clin Pharmacol TherEscitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real‐life studies show a high degree of genotype–phenotype mismatch in escitalopram metabolism.
Hole K +3 more
europepmc +2 more sources
Clinical and Translational Science, 2022 This study evaluated the effect of repeated doses of elagolix on the pharmacokinetics (PK) of omeprazole and its metabolites in healthy premenopausal female subjects. Adult premenopausal female subjects (N = 20) received a single oral dose of omeprazole (
Ahmed Nader +3 more
doaj +1 more source
Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. [PDF]
PLoS ONE, 2014 Benzimidazole drugs lansoprazole and omeprazole are used for treatment of various gastrointestinal pathologies. Both compounds cause drug-drug interactions because they activate aryl hydrocarbon receptor and induce CYP1A genes.
Aneta Novotna, Zdenek Dvorak
doaj +1 more source